Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Shigella flexneri 6 O-antigen polysaccharide is a component of the lipopolysaccharide (LPS) outer membrane of Shigella flexneri serotype 6 bacteria, differing from the common backbone shared by most other S. flexneri serotypes (e.g., serotype Y). It consists of repeating oligosaccharide units that contribute to serotype specificity through structural variations, including potential phage-mediated modifications like glucosylation or O-acetylation, though specific modifications for serotype 6 are less detailed compared to others. This polysaccharide is recognized by antibodies such as those in serological assays and plays a key role in eliciting host immune responses, making it relevant for vaccine development targeting Shigella infections. Structural studies note its distinction from the basic tetrasaccharide repeat [→3)-β-D-GlcpNAc-(1→2)-α-L-RhapII-(1→2)-α-L-RhapIII-(1→3)-α-L-RhapI-(1→ of serotype Y, with serotype 6 sharing some group 1 antigen features but having a unique O-antigen profile. Conformational flexibility, potentially helical, aids in antibody binding and immune evasion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shigella flexneri 6 O-antigen polysaccharide.